CatalYm

Summary

Seedtable Score

69

Locations

• Munich

Company Size

• 11 - 51

Last Stage Round

• Series D

Industry

• Biotech
• Health Tech

Insights

CatalYm shows strong potential with its focus on innovative immunotherapies for cancer patients. Based in Munich, it operates on a B2B model, supplying treatments to healthcare businesses. Backing from investors like Forbion Capital and Novartis Venture Fund indicates confidence in CatalYm's scientific approach and market potential. Unlike traditional cancer treatments like chemotherapy and radiation, which often have significant drawbacks, CatalYm aims to offer more effective, targeted solutions. By concentrating on pioneering immunotherapy approaches, the company is well-positioned to improve patient outcomes and set new standards in cancer care.

• Unknown (2022) $51.6M

---

• Series D (2024) $150M

---

• Series B (2020-01-01) $59.0M

---

Investors

• Forbion Capital Partners Unknown

---

• Forbion Capital Partners Unknown

---

• Vesalius Biocapital Partners Unknown

---

• Novartis Venture Fund Unknown

---

• Bayern Kapital Unknown

---

• Bayern Kapital Unknown

---

• Coparion Unknown

---

• Brandon Capital Series D

---

• Bioqube Ventures Series D

---

• Canaan Partners Series D

---

• Novartis Venture Fund Series D

---

• Forbion Capital Partners Series B

---

• Forbion Capital Partners Series B

---

• Vesalius Biocapital Partners Series B

---

• Novartis Venture Fund Series B

---

Full Company Profile

Access details of the company management, and other intelligence on this company by registering for Seedtable

---